FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
about
Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial dataIron therapy in anaemic adults without chronic kidney diseaseEfficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemiaThe role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal diseaseIron deficiency anemia in inflammatory bowel diseaseAnemia in inflammatory bowel disease: a neglected issue with relevant effectsAnemia in inflammatory bowel disease: an under-estimated problem?Pre-operative anaemiaPrevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. ironAnemia and iron deficiency in gastrointestinal and liver conditionsIron Replacement in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysisEfficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled TrialsEvaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled studySafety and Efficacy of Ferric Carboxymaltose in Anemic Pregnant Women: A Retrospective Case Control StudyEffect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemiaFerric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency.Iron deficiency anaemia in patients with inflammatory bowel disease: National Consultant for Gastroenterology Working Group RecommendationsA Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapySpanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document".Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases.The effect of intravenous iron treatment on quality of life in inflammatory bowel disease patients with nonanemic iron deficiency.Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic ReviewMulticentre randomized controlled trial comparing ferric(III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients.Iron therapy for the treatment of preoperative anaemia in patients with colorectal carcinoma: a systematic review.The safety and efficacy of high dose ferric carboxymaltose in patients with chronic kidney disease: A single center studyEfficacy and Safety of Intravenous Ferric Carboxymaltose in Geriatric Inpatients at a German Tertiary University Teaching Hospital: A Retrospective Observational Cohort Study of Clinical Practice.Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations.Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemiaChoice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia RiskA 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease.Diluting ferric carboxymaltose in sodium chloride infusion solution (0.9% w/v) in polypropylene bottles and bags: effects on chemical stability.Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemiaA fast-track anaemia clinic in the Emergency Department: feasibility and efficacy of intravenous iron administration for treating sub-acute iron deficiency anaemiaManagement of Iron Deficiency Anemia.Iron deficiency anemia in patients with inflammatory bowel disease.
P2860
Q21261840-FE35D782-F0AF-4979-BD8C-CCD1E299D40EQ24187098-65F62BAF-F4C2-454A-A8F6-9A09BE518EA7Q26750413-99D98CB9-E330-4497-BE06-A7423DB8F7B9Q26771882-8DE6EE6A-D4EF-459F-A46B-4CACF4520609Q26795390-EDDA9955-395E-483F-881D-65CD6CAA1154Q26822906-49DC9244-0C84-4C95-95BC-B6C2CEED4849Q26860882-07DF3838-051C-49BF-A65E-7DAB1F716EB2Q26998362-73C98D75-8CAF-43D5-BF4A-8772DDA52673Q27004170-3EF00106-D7D1-43A7-AAFA-8AD8FBB5A3B4Q28069820-E308D1DC-A435-425D-BB65-812C0D38B60BQ28082489-07A3755A-F5A6-4069-B8F3-F6B44F4310CCQ28085514-B1B7968D-101B-4B8A-B0C5-89DAF9994EE3Q28538067-20293ABB-FCDB-4CD6-A742-0F6F34D14C88Q28606630-919E5B97-68CA-4578-9F22-27A4F7FECCDFQ28730674-3FB8AD37-E033-45A8-A989-1D7851F17F09Q31103631-8AA7122D-B3F6-4ECA-984F-1676C6EACF30Q34041875-403E751E-A5D9-4A66-B2EB-004C71D819DFQ34429565-5D9634A1-EC64-4823-A33F-B4F687E1136EQ34466623-32DE510D-67BD-47C8-8D4C-4768CE92878EQ34477467-1531164D-B4E5-46D7-99B3-75CF76FE56A8Q34654443-7385C57C-54BE-4669-BA4A-CA47D9CB0057Q34700903-B1DD530E-F11C-49C8-BAF1-8C90468A948EQ34867539-0325F41A-7C65-4B5C-8367-F6F40E64C30EQ35063802-ACB7FAEC-A21E-4D6E-8F6A-2E17A57948F4Q35126117-6EF77AC3-4D73-42FD-AB26-9774C2929F4BQ35642045-0AB89948-F0B4-42BE-8089-04B44344D2DCQ35659768-B7610803-00A5-49A6-B298-7C125771DA86Q35677958-994C99D7-1704-4C0A-BB91-DEFC2657AAE2Q35765232-C915233B-CCB4-4D5B-8933-0E7D12793196Q35830277-AF9ADAA4-4FB4-4BDD-ABC3-61A86333B184Q35864436-55516D6E-2B09-43BE-B604-E0EE573125F2Q35898038-016F2952-4CCE-4253-8A73-DA4AFAD090EBQ36086930-F4874EE9-56E9-419F-8633-4BE98D7F89DBQ36209885-C15F1FE2-33A2-4790-A793-E938487FFC47Q36357208-A2F9B640-80D7-443C-955F-99582AC89F09Q36475511-C83CABE0-CF19-4B71-841E-F85005492C6EQ36551637-2C1AC271-0233-4EE3-B60C-7065B27C7797Q36660755-C493806B-2D03-4D0B-AFD9-14801B6D3EF5Q36812538-99E23B7A-2C9A-4723-B02F-FA28243A59C4Q36918762-08258826-6B4A-4861-AFB1-0A203125D36F
P2860
FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
FERGIcor, a randomized control ...... in inflammatory bowel disease.
@ast
FERGIcor, a randomized control ...... in inflammatory bowel disease.
@en
FERGIcor, a randomized control ...... in inflammatory bowel disease.
@nl
type
label
FERGIcor, a randomized control ...... in inflammatory bowel disease.
@ast
FERGIcor, a randomized control ...... in inflammatory bowel disease.
@en
FERGIcor, a randomized control ...... in inflammatory bowel disease.
@nl
prefLabel
FERGIcor, a randomized control ...... in inflammatory bowel disease.
@ast
FERGIcor, a randomized control ...... in inflammatory bowel disease.
@en
FERGIcor, a randomized control ...... in inflammatory bowel disease.
@nl
P2093
P50
P1433
P1476
FERGIcor, a randomized control ...... in inflammatory bowel disease
@en
P2093
Bernd Bokemeyer
FERGI Study Group
Igor L Khalif
Ivan V Chopey
Lise Riopel
Philippe Marteau
Rayko Evstatiev
Tariq Iqbal
P304
846-853.e1-2
P356
10.1053/J.GASTRO.2011.06.005
P407
P577
2011-06-12T00:00:00Z